2105 Stock Chart & Stats
HK$14.85
-HK$0.72(-6.22%)
At close: 4:00 PM EST
HK$14.85
-HK$0.72(-6.22%)
Day’s Range― - ―
52-Week RangeHK$5.37 - HK$19.36
Previous CloseN/A
Volume9.24M
Average Volume (3M)1.82M
Market Cap
HK$3.45B
Enterprise ValueHK$1.64B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding452,061,340
10 Day Avg. Volume1,732,800
30 Day Avg. Volume1,815,838
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.17
Revenue Forecast (FY)HK$317.01M
Laekna, Inc. News
2105 FAQ
What was Laekna, Inc.’s price range in the past 12 months?
Laekna, Inc. lowest stock price was HK$5.37 and its highest was HK$19.36 in the past 12 months.
What is Laekna, Inc.’s market cap?
Laekna, Inc.’s market cap is HK$3.45B.
When is Laekna, Inc.’s upcoming earnings report date?
Laekna, Inc.’s upcoming earnings report date is Mar 30, 2027 which is in 174 days.
How were Laekna, Inc.’s earnings last quarter?
Laekna, Inc. released its earnings results on Aug 25, 2026. The company reported -HK$0.012 earnings per share for the quarter.
Is Laekna, Inc. overvalued?
According to Wall Street analysts Laekna, Inc.’s price is currently Overvalued.
Does Laekna, Inc. pay dividends?
Laekna, Inc. does not currently pay dividends.
What is Laekna, Inc.’s EPS estimate?
Laekna, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Laekna, Inc. have?
Laekna, Inc. has 452,061,340 shares outstanding.
What happened to Laekna, Inc.’s price movement after its last earnings report?
Laekna, Inc. reported an EPS of -HK$0.012 in its last earnings report. Following the earnings report the stock price went down -3.299%.
Which hedge fund is a major shareholder of Laekna, Inc.?
Currently, no hedge funds are holding shares in HK:2105
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Laekna, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
62.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Laekna, Inc.
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE111, LAE112, LAE113, LAE119, and LAE120 for the treatment of cancer; LAE118, a PI3Ka mutant-selective inhibitor; LAE103 for Sarcopenia; LAE123 to treat muscle and other disease indications; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. The company has a collaboration with Eli Lilly and Company for the development of LAE102. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China.
Technical Analysis
Antengene Corporation Limited
―
Genor Biopharma Holdings Limited
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―